

OncoGeneDx: Hereditary MDS/Leukemia Panel

Panel Gene List: *ANKRD26*, *CEBPA**, *DDX41*, *ETV6*, *GATA2*, *RUNX1*, *SAMD9*, *SAMD9L*, *SRP72*, *TERC*, *TERT*, *TP53*

*Testing includes sequencing and deletion/duplication analysis for all genes except *CEBPA* (seq only).

Clinical Features:

In the general population, approximately 1.5% of individuals will develop leukemia in their lifetime.¹ Most hematological malignancies develop sporadically; however, approximately 11% to 18% of hematological cancer cases are thought to be due to a hereditary predisposition.²⁻⁴ Features suggestive of hereditary hematological cancer predisposition may include early age of diagnosis of leukemia or myelodysplastic syndrome (MDS), multiple family members affected with thrombocytopenia, aplastic anemia, hematological cancer, or MDS, and in some cases, the presence of certain solid tumors or other health problems in the family.

The OncoGeneDx Hereditary MDS/Leukemia Panel includes analysis of 12 cancer predisposition genes that have been implicated in hematological malignancy predisposition. This panel includes *TP53*, which is associated with Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome with consensus management guidelines. Additionally, pathogenic variants in *TERC* and *TERT* (dyskeratosis congenita/telomere disorder), *SAMD9*, and *SAMD9L* have published expert opinion management guidelines available.^{5,6} Pathogenic variants in *ANKRD26*, *CEBPA*, *DDX41*, *ETV6*, *GATA2*, *RUNX1*, and *SRP72* have also been reported in association with hereditary hematological malignancy. Since the cancer risks for these seven genes are not yet well defined, no consensus medical management guidelines have been published. However, surveillance and management recommendations for individuals with genetic predisposition to hematologic malignancies are available.⁷ The cancers that are associated with pathogenic variants in each of the genes are outlined in the table below.

Inheritance Pattern:

All of the genes on this panel are associated with autosomal dominant cancer risk. Additionally, inheritance of biallelic pathogenic variants in *SAMD9* are associated with normophosphatemic familial tumoral calcinosis while biallelic pathogenic variants in *TERT* are associated with a severe autosomal recessive form of dyskeratosis congenita. The specifics of this inheritance are outlined in the table below.

Specimen Requirements:

Cultured skin fibroblasts are the preferred specimen type for germline genetic testing in individuals who may have acquired somatic mutations in their peripheral blood lymphocytes (active leukemias, chronic leukemias, myeloproliferative disorders, active forms of some lymphomas).

Blood, oral rinse, and buccal specimens are generally acceptable for individuals with active or past histories of a hematologic disease type that does not typically infiltrate the peripheral blood (Hodgkin lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, multiple myeloma, others).

Please visit the specimen requirements section of the GeneDx website for additional information on sample types.

Test Methods:

Genomic DNA is extracted from the submitted specimen. For skin punch biopsies, fibroblasts are cultured and used for DNA extraction. The DNA is enriched for the complete coding regions and splice junctions of the genes on this panel using a proprietary targeted capture system developed by GeneDx for next-generation sequencing with CNV calling (NGS-CNV). The enriched targets are simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads are assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. After gene specific filtering, data are analyzed to identify sequence variants and most deletions and duplications involving coding exons; however, technical limitations and inherent sequence properties effectively reduce this resolution for some genes. For *CEBPA*, only sequencing is performed. Alternative sequencing or copy number detection methods are used to analyze or confirm regions with inadequate sequence or copy number data by NGS. Reportable variants include pathogenic variants, likely pathogenic variants and variants of uncertain significance. Likely benign and benign variants, if present, are not routinely reported but are available upon request.

Test Sensitivity:

The clinical sensitivity of sequencing and deletion/duplication analysis of the 12 genes included in the OncoGeneDx Hereditary MDS/Leukemia Panel depends in part on the patient's clinical phenotype and family history. In general, the sensitivity is highest for individuals with features suggestive of a hereditary predisposition to cancer as outlined above. DNA sequencing will detect nucleotide substitutions and small insertions and deletions, while NGS-CNV analysis, array CGH, or MLPA will detect exon-level deletions and duplications. These methods are expected to be greater than 99% sensitive in detecting pathogenic variants identifiable by sequencing or CNV technology.

Genetic testing using the methods applied at GeneDx is expected to be highly accurate. Normal findings do not rule out the diagnosis of a genetic disorder since some genetic abnormalities may be undetectable by this test. The methods used cannot reliably detect deletions of 20bp to 250bp in size, or insertions of 10bp to 250 bp in size. Sequencing cannot

detect low-level mosaicism. The copy number assessment methods used with this test cannot reliably detect mosaicism and cannot identify balanced chromosome aberrations. Rarely, incidental findings of large chromosomal rearrangements outside the gene of interest may be identified. Regions of certain genes have inherent sequence properties (for example: repeat, homology, or pseudogene regions, high GC content, rare polymorphisms) that yield suboptimal data, potentially impairing accuracy of the results. False negatives may also occur in the setting of bone marrow transplantation, recent blood transfusion, or suboptimal DNA quality. In individuals with active or chronic hematologic neoplasms or conditions, there is a possibility that testing may detect an acquired somatic variant, resulting in a false positive result. As the ability to detect genetic variants and naming conventions can differ among laboratories, rare false negative results may occur when no positive control is provided for testing of a specific variant identified at another laboratory. The chance of a false positive or false negative result due to laboratory errors incurred during any phase of testing cannot be completely excluded. Interpretations are made with the assumption that any clinical information provided, including family relationships, are accurate. Consultation with a genetics professional is recommended for interpretation of results.

Gene	Protein	Inheritance	Disease Associations
<i>ANKRD26</i> ⁸⁻¹¹	ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 26	AD	Thrombocytopenia-2: Myeloid malignancies (AML, MDS, CML)
<i>CEBPA</i> ^{12,13}	CCAAT/ENHANCER-BINDING PROTEIN, ALPHA	AD	CEBPA-associated familial acute myeloid leukemia: AML
<i>DDX41</i> ¹⁴⁻¹⁶	DEAD/H BOX 41	AD	AML, MDS
<i>ETV6</i> ^{17,18}	ETS VARIANT GENE 6	AD	Thrombocytopenia-5: MDS, AML, ALL
<i>GATA2</i> ¹⁹⁻²³	GATA-BINDING PROTEIN 2	AD	Familial MDS/AML, monocytopenia and mycobacterial infection (MonoMAC) syndrome, Emberger syndrome
<i>RUNX1</i> ²⁴⁻²⁷	RUNT-RELATED TRANSCRIPTION FACTOR 1	AD	Familial platelet disorder with propensity to acute myeloid leukemia (FPD/AML), MDS
<i>SAMD9</i> ^{6,28-32}	STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 9	AD	AML, MDS; Myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy (MIRAGE) syndrome
		AR	Normophosphatemic familial tumoral calcinosis (NFTC)
<i>SAMD9L</i> ^{6,32-34}	STERILE ALPHA MOTIF DOMAIN-CONTAINING	AD	AML, MDS, Ataxia–pancytopenia syndrome (ATXPC)

	PROTEIN 9-LIKE SIGNAL RECOGNITION PARTICLE, 72-KD	AD	MDS, aplastic anemia, pancytopenia
<i>SRP72</i> ³⁵			
<i>TERC</i> ³⁶⁻⁴²	TELOMERASE RNA COMPONENT	AD	Dyskeratosis Congenita (DC): AML, MDS, BMF, head and neck squamous cell carcinoma, anogenital cancers
<i>TERT</i> ^{36,38,39,41-44}	TELOMERASE REVERSE TRANSCRIPTASE	AD	Dyskeratosis Congenita (DC): AML, MDS, BMF, head and neck squamous cell carcinoma, anogenital cancers
		AR	Hoyeraal-Hreidarsson (HH) syndrome
<i>TP53</i> ⁴⁵⁻⁵⁰	CELLULAR TUMOR ANTIGEN P53	AD	Li-Fraumeni syndrome (LFS): breast cancer, sarcoma, brain cancer, hematologic malignancies, adrenocortical carcinoma, among others**

Because of evolving and expanding phenotypes, this list of cancer/tumor types is not exhaustive. Gene-specific risk for some of the cancers and other features listed are not well-defined.

** High overall risk of cancer: 75% lifetime risk for males to develop cancer, nearly 100% risk for females.

Abbreviations:

AD – Autosomal dominant

ALL – Acute lymphoblastic leukemia

AML – Acute myeloid leukemia

AR – Autosomal recessive

BMF – Bone marrow failure

CGH – Comparative genomic hybridization

CML – Chronic myeloid leukemia

MDS – Myelodysplastic syndrome

MLPA – Multiplex ligation-dependent probe amplification

References:

1. Probability of Developing or Dying of Cancer - Surveillance Research Program. Available at: <https://surveillance.cancer.gov/devcan/>. (Accessed: 18th September 2017)
2. Keel, S. B. *et al.* Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. *Haematologica* **101**, 1343–1350 (2016).
3. DiNardo, C. D. *et al.* Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). *Clin. Lymphoma Myeloma Leuk.* **16**, 417-428.e2 (2016).
4. Zhang, M. Y. *et al.* Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. *Haematologica* **100**, 42–48 (2015).
5. DCOWriter. DC Clinical Guidelines. *DC Outreach* (2015). Available at: <https://www.dcoutreach.org/guidelines>. (Accessed: 30th April 2018)
6. Davidsson, J. *et al.* SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies. *Leukemia* **32**, 1106–1115 (2018).
7. Godley, L. A. & Shimamura, A. Genetic predisposition to hematologic malignancies: management and surveillance. *Blood* **130**, 424–432 (2017).
8. Noris, P. *et al.* ANKRD26-related thrombocytopenia and myeloid malignancies. *Blood* **122**, 1987–1989 (2013).
9. Pippucci, T. *et al.* Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. *Am. J. Hum. Genet.* **88**, 115–120 (2011).
10. Averina, M., Jensvoll, H., Strand, H. & Sovershaev, M. A novel ANKRD26 gene variant causing inherited thrombocytopenia in a family of Finnish origin: Another brick in the wall? *Thromb. Res.* **151**, 41–43 (2017).
11. Ferrari, S. *et al.* Spectrum of 5'UTR mutations in ANKRD26 gene in patients with inherited thrombocytopenia: c.-140C>G mutation is more frequent than expected. *Platelets* **28**, 621–624 (2017).
12. Tawana, K. & Fitzgibbon, J. CEBPA-Associated Familial Acute Myeloid Leukemia (AML). in *GeneReviews*[®] (eds. Adam, M. P. *et al.*) (University of Washington, Seattle, 1993).
13. Tawana, K. *et al.* Disease evolution and outcomes in familial AML with germline CEBPA mutations. *Blood* **126**, 1214–1223 (2015).
14. Cardoso, S. R. *et al.* Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. *Leukemia* **30**, 2083–2086 (2016).

15. Lewinsohn, M. *et al.* Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. *Blood* **127**, 1017–1023 (2016).
16. Li, R., Sobreira, N., Witmer, P. D., Pratz, K. W. & Braunstein, E. M. Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia. *Haematologica* **101**, e228-231 (2016).
17. Feurstein, S. & Godley, L. A. Germline ETV6 mutations and predisposition to hematological malignancies. *Int. J. Hematol.* **106**, 189–195 (2017).
18. Dirse, V. *et al.* ETV6 and NOTCH1 germline variants in adult acute leukemia. *Leuk. Lymphoma* **59**, 1022–1024 (2018).
19. Hsu, A. P. *et al.* Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. *Blood* **118**, 2653–2655 (2011).
20. Ostergaard, P. *et al.* Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). *Nat. Genet.* **43**, 929–931 (2011).
21. Spinner, M. A. *et al.* GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. *Blood* **123**, 809–821 (2014).
22. Kazenwadel, J. *et al.* Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. *Blood* **119**, 1283–1291 (2012).
23. Wlodarski, M. W. *et al.* Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. *Blood* **127**, 1387–1397; quiz 1518 (2016).
24. Latger-Cannard, V. *et al.* Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. *Orphanet J. Rare Dis.* **11**, 49 (2016).
25. Liew, E. & Owen, C. Familial myelodysplastic syndromes: a review of the literature. *Haematologica* **96**, 1536–1542 (2011).
26. Owen, C. J. *et al.* Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. *Blood* **112**, 4639–4645 (2008).
27. Preudhomme, C. *et al.* High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. *Blood* **113**, 5583–5587 (2009).
28. Topaz, O. *et al.* A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. *Am. J. Hum. Genet.* **79**, 759–764 (2006).
29. Chefetz, I. *et al.* Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF-alpha responsive protein. *J. Invest. Dermatol.* **128**, 1423–1429 (2008).
30. Jeffries, L. *et al.* A novel SAMD9 mutation causing MIRAGE syndrome: An expansion and review of phenotype, dysmorphology, and natural history. *Am. J. Med. Genet. A.* **176**, 415–420 (2018).
31. Narumi, S. *et al.* SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. *Nat. Genet.* **48**, 792–797 (2016).
32. Nagata, Y. *et al.* Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. *Blood* **132**, 2309–2313 (2018).
33. Phowthongkum, P., Chen, D.-H., Raskind, W. H. & Bird, T. SAMD9L-Related Ataxia-Pancytopenia Syndrome. in *GeneReviews*[®] (eds. Adam, M. P. *et al.*) (University of Washington, Seattle, 1993).
34. Thunström, S. & Axelsson, M. Leukoencephalopathy, demyelinating peripheral neuropathy and dural ectasia explained by a not formerly described de novo mutation in the SAMD9L gene, ends 27 years of investigations - a case report. *BMC Neurol.* **19**, 89 (2019).
35. Kirwan, M. *et al.* Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. *Am. J. Hum. Genet.* **90**, 888–892 (2012).
36. Savage, S. A. Dyskeratosis Congenita. in *GeneReviews*[®] (eds. Adam, M. P. *et al.*) (University of Washington, Seattle, 1993).
37. Yamaguchi, H. *et al.* Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. *Blood* **102**, 916–918 (2003).
38. Savage, S. A. & Bertuch, A. A. The genetics and clinical manifestations of telomere biology disorders. *Genet. Med. Off. J. Am. Coll. Med. Genet.* **12**, 753–764 (2010).
39. Bessler, M., Du, H.-Y., Gu, B. & Mason, P. J. Dysfunctional telomeres and dyskeratosis congenita. *Haematologica* **92**, 1009–1012 (2007).
40. Vulliamy, T. *et al.* Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. *Nat. Genet.* **36**, 447–449 (2004).
41. Bessler, M., Wilson, D. B. & Mason, P. J. Dyskeratosis congenita. *FEBS Lett.* **584**, 3831–3838 (2010).
42. Du, H.-Y. *et al.* TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. *Blood* **113**, 309–316 (2009).
43. Yamaguchi, H. *et al.* Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. *N. Engl. J. Med.* **352**, 1413–1424 (2005).
44. Basel-Vanagaite, L. *et al.* Expanding the clinical phenotype of autosomal dominant dyskeratosis congenita caused by TERT mutations. *Haematologica* **93**, 943–944 (2008).
45. Olivier, M. *et al.* Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res.* **63**, 6643–6650 (2003).
46. Pennington, K. P. *et al.* BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. *Cancer* **119**, 332–338 (2013).
47. Chompret, A. *et al.* P53 germline mutations in childhood cancers and cancer risk for carrier individuals. *Br. J. Cancer* **82**, 1932–1937 (2000).
48. Gonzalez, K. D. *et al.* Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **27**, 1250–1256 (2009).
49. Ruijs, M. W. G. *et al.* TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. *J. Med. Genet.* **47**, 421–428 (2010).
50. Hisada, M., Garber, J. E., Fung, C. Y., Fraumeni, J. F. & Li, F. P. Multiple primary cancers in families with Li-Fraumeni syndrome. *J. Natl. Cancer Inst.* **90**, 606–611 (1998).